Marco Montillo

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny et al. · Journal of Clinical Oncology · 2010 · 475 citations · Full text

Medicine, Immunology, Oncology +16

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Talha Munir, Jennifer R. Brown, Susan O’Brien et al. · American Journal of Hematology · 2019 · 473 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Wolfgang Knauf, Toshko Lissichkov, Ali Aldaoud et al. · Journal of Clinical Oncology · 2009 · 439 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8